

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

NOVO NORDISK A/S,
Patent Owner

Case IPR2023-00724
Patent 10,335,462

NOTICE OF DEPOSITION OF PAUL DALBY, PH.D.

Pursuant to 37 C.F.R. §42.53, Patent Owner Novo Nordisk A/S (“Novo”), by and through its attorneys, will conduct cross-examination by deposition of Paul Dalby, Ph.D. Dr. Dalby’s deposition will take place on January 8, 2024, commencing at 10:00 AM EST on each day, and continuing from day-to-day if necessary, via remote audio-video conference via a remote platform.

The cross-examination will be taken before a Notary Public or other officer authorized by law to administer oaths. It will be recorded by using stenographic means or a digital reporter. Novo further reserves the right to utilize the following: (1) record the deposition using audio technology; (2) instant visual display such that the reporter’s writing of the proceeding will be available to all who are a party to this proceeding to request and receive it in real time; (3) exhibit capture (picture-in-picture) technology in which any exhibit reviewed by the deponent during the deposition can be captured visually; and (4) to conduct this deposition using a paperless exhibit virtual display platform. The arrangement for the reporter will be made by counsel for Novo.

Respectfully submitted,

IPR2023-00724
U.S. Patent 10,335,462
Dated: December 15, 2023

By: /Megan Raymond/

J. Steven Baughman (Reg. No. 47,414)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5832
steve.baughman@groombridgewu.com

Megan Raymond (Reg. No. 72,997)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5878
megan.raymond@groombridgewu.com

Attorneys for Patent Owner Novo Nordisk A/S

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of NOTICE OF DEPOSITION OF PAUL DALBY, PH.D. has been served in its entirety by causing the aforementioned document to be electronically mailed to the following attorneys of record for Petitioner listed below:

Petitioner's Counsel of Record:

Lead Counsel:	Brandon M. White Reg. No. 52,354 White-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200 By Electronic Mail
Backup Counsel:	Emily J. Greb Reg. No. 68,244 Greb-ptab@perkinscoie.com Perkins Coie LLP 33 East Main Street Madison, WI 53703 Telephone: (608) 663-7460 Courtney Prochnow, PhD Reg. No. 67,639 Prochnow-ptab@perkinscoie.com Perkins Coie LLP 633 W. 5th St., Ste 5850 Los Angeles, CA 90071 Telephone: (310) 788-9900 Christopher D. Jones Reg. No. 76,472

	<p>Jones-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200</p> <p>Jonathan I. Tietz, PhD Reg. No. 76,753 Tietz-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200</p> <p>Matthew A. Lembo Reg. No. 75,633 Lembo-ptab@perkinscoie.com Perkins Coie LLP 1155 Avenue of the Americas Floor 22 New York, NY 10036 Telephone: (212) 262-6900</p> <p><u>Semaglutide-Ozempic@perkinscoie.com</u> By Electronic Mail</p>
--	---

Dated: December 15, 2023

Respectfully submitted,

By: /Sayem Osman /
Sayem Osman